echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > After "4 + 7" volume procurement, domestic antihypertensive drugs will be "in bud"

    After "4 + 7" volume procurement, domestic antihypertensive drugs will be "in bud"

    • Last Update: 2019-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network market analysis] sleepless, headache, dizziness Because of the aging and irregular life rhythm, more and more patients with hypertension are now suffering According to the data of China CDC, the number of hypertension patients in China has reached nearly 300 million The increase of patients with hypertension also brings huge market opportunities to the market of antihypertensive drugs As a result, global pharmaceutical companies have also flocked to our country to launch new drugs, and antihypertensive drugs are also showing a blooming scene At the same time, through more than 70 years of innovation and development, China's local antihypertensive drugs have also made great progress It is understood that through more than 70 years of development, China's antihypertensive drugs have gone through the road from less to more, from high price to low price No matter the antihypertensive No 0 or the imported product, luohuoxi, which is independently developed in China, has become the representative drug in the antihypertensive drug market, benefiting countless patients In recent years, with the introduction of "4 + 7" purchasing policy and other policies, the price of drugs has been greatly reduced, and the market of antihypertensive drugs may face a new round of opportunities and challenges Health Care Commission staff said that after the implementation of centralized drug procurement, the price of domestic drugs has declined, and there are safer and more affordable alternative drugs for people to choose In addition, industry analysis shows that in the context of medical insurance and cost control, with the completion of generic drug consistency evaluation, domestic antihypertensive drugs will be more competitive With the advantages of quality, curative effect and cost performance, it will cannibalize the market of city level hospitals of foreign-funded enterprises It is understood that calcium channel blockers, angiotension II receptor antagonists (ARBs) and compound preparations account for the majority of the market share of various antihypertensive drugs in China, accounting for 35%, 26% and 16% respectively However, it is worth noting that for a large population of patients with hypertension, many antihypertensive drugs have disadvantages such as side effects, poor bioavailability and inadequate applicability It is understood that in the market competition, the performance of domestic generic drugs with low price is unsatisfactory According to the data of China Pharmaceutical Industry Information Center, the top ten antihypertensive drugs in the sales volume of hospitals in key cities are all original research drugs, 9 of which are imported drugs, among which 5 antihypertensive drugs listed in the above research are all included; only one is produced by domestic pharmaceutical enterprises Experts said that although the ingredients of imported drugs and generic drugs are the same, there are some differences in production process and product quality "The reason why patients hesitate to choose domestic generic drugs is that they have some concerns about their efficacy and adverse reactions Therefore, improving the quality of domestic generic drugs is the fundamental way to solve the problem of expensive drugs for patients." Now, with the introduction of "4 + 7" volume procurement, generic drug consistency evaluation and other policies, the quality of domestic antihypertensive drugs may be greatly improved, and the market may also get a new breakthrough But when it comes to the future of antihypertensive drugs, experts point out that innovative drugs are always the direction of market development With the help of nano sustained-release technology, the sustained-release dosage forms of antihypertensive drugs may become the focus of research and development in the future, and pharmaceutical companies will also take this opportunity to break through the scattered pattern, improve their own advantages, and achieve integration and upgrading In addition, some industry people also put forward the new idea of "secondary development" of old brand innovative drugs The person said that the old brand domestic innovative drugs could try to "rebirth", that is, research and develop new means on the original basis Take the antihypertensive drug as an example, "if one tablet can be taken in one week in the future, the compliance of patients will be greatly improved In this way, the old brand domestic innovative drug will take another step Some industry insiders also said that domestic pharmaceutical enterprises need to cooperate in tackling key problems and control costs to make antihypertensive drugs In terms of cost control, we can learn from foreign experience and play the role of "leverage" of medical insurance Now with the promotion of 4 + 7 policy and the reduction of drug price, more patients will accept domestic antihypertensive drugs "I believe that in the future, we can definitely use more affordable antihypertensive drugs." One patient said But the industry said that if domestic antihypertensive drugs want to better seize the broad market, they must first do a good job in quality, production of high-quality, effective products can have more say.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.